Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)

Ying Liao; Changhua Zhu; Xiaoxia Song; Jiugen Ruan; Yao Ding; Yuan Chen; Qiujuan Yang

doi:10.12659/MSM.934493

24 March 2022: Clinical Research

Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)

Ying Liao ^1BCE , Changhua Zhu ^2A* , Xiaoxia Song ^1CF , Jiugen Ruan ^2BCDF , Yao Ding ^2CF , Yuan Chen ^3BCDEF , Qiujuan Yang ^1F

DOI: 10.12659/MSM.934493

Med Sci Monit 2022; 28:e934493

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 3 (A–D) Patients were diagnosed with advanced endometrial cancer by MRI. The figure was edited using Microsoft PowerPoint 2010 (Microsoft, Redmond, WA, USA) from a screenshot from the Medixant, RadiAnt DICOM Viewer (version 2020.2.3) in our institution.

Back to the Article

Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)

Your Privacy